BRAF and metastatic malignant neoplasm in the lymph nodes: Since HT can counteract the effect of BRAF mutation and neutralize the risk of lymph node metastasis in PTC patients [17], this specific subset of patients may maintain treatment as if harboring a wild type PTC.